| Jan. 15, 2012 |
- |
Enlivex has completed patient enrollment in its Phase I/II clinical trial
|
|
| Jan. 10, 2012 |
- |
Thrombotech Completes Additional Financing Round of $1.4 million
|
|
| Nov. 27, 2011 |
- |
Recommendation to terminate Verto’s activity - not expected to affect company.
|
|
| Nov. 14, 2011 |
- |
4 portfolio companies have received government grants for over 10 M NIS in 2011
|
|
| Oct. 30, 2011 |
- |
BioMarCare receives approval for use of 400 samples from the Hadassah Medical Center
|
|
| Jul. 6, 2011 |
- |
BioMarCare Ltd. receives initial approval for a grant from the BIRD Foundation
|
|
| Jul. 3, 2011 |
- |
HBL announces that Thrombotech has begun its Phase IIa clinical trial
|
|
| Jun. 27, 2011 |
- |
Hadasit Bio-Holdings Begins Trading in U.S. through Launch of ADR
|
|
| Jun. 20, 2011 |
- |
BNY Mellon Appointed as Depositary Bank by Hadasit Bio-Holdings, Ltd.
|
|
| Jun. 19, 2011 |
- |
HBL announces an ADS trading program in the United States (OTCBB:HADSY)
|
|
| Apr. 14, 2011 |
- |
KAHR Medical to Raise $ 3 M for Development of Novel Cancer and Autoimmune Disease Drugs
$2 million will be invested by the European drug giant Sanofi-Aventis
|
|
| Mar. 9, 2011 |
- |
Poalim Sahar initiates coverage on HBL
Analyst sets target share price at 2.1 NIS (100% upside)
|
|
| Mar. 6, 2011 |
- |
BioMarCare financing and clinical trial
BioMarCare receives financing and Helsinki approval for clinical trial
|
|
| Dec. 26, 2010 |
- |
Hadasit Bio-Holdings facilitates foreign investment in the traded stock (TASE:HDST)
We are happy to provide an easy and convenient investment tool for our international investors
|
|
| Oct. 10, 2010 |
- |
HBL's subsidiary- CellCure makes the deal of the year
TEVA, BioTime and HBL invest $7.1 M. and sign an exclusive license option agreement with TEVA
|
|
| Sep. 28, 2010 |
- |
HBL and BioMarCare get positive PR from top IBI analyst in Globes
Investment recommendations from Elah Alkalay VP BD at IBI
|
|
| Aug. 31, 2010 |
- |
Report by Globes on TASE Offering
"Hadasit Bio Holdings Raises NIS 11.5m in TASE Offering"
|
|
| Aug. 31, 2010 |
- |
Successful Public Offering
HBL Announces a Successful Public Offering on the TASE - Over 11 Million NIS Raised
|
|
| Aug. 24, 2010 |
- |
Another Major Achievement for Hadasit Bio Holdings (Thrombotech completes phase I)
Thrombotech, a subsidiary of Hadasit Bio Holdings, successfully completed Phase I trial
|
|
| Aug. 19, 2010 |
- |
Q2 2010 report (capital gain of 13 million NIS)
The company reports first substantial capital gain of 13 million NIS
|
|
| Aug. 16, 2010 |
- |
Exclusive Licensing Agreement
BioMarCare Technologies, a subsidiary of Hadasit Bio-Holdings, Has Signed an Exclusive Licensing Agreement with Hadasit for the Commercialization of an Innovative Marker Enabling Early Detection of Cancer
|
|
| Jul. 29, 2010 |
- |
Spotlight on HBL - in "Globes"
"The TASE BioMed Index's Favorite Seeking Partnerships"
|
|
| Jun. 14, 2010 |
- |
3 of HBL's Portfolio Companies Appear in "Israel's Most Promising BioTech Statups" List
ProtAb, KAHR and CellCure included in the list
|
|
| Jun. 13, 2010 |
- |
From Test Tube to Bedside
Israel's only hospital affiliated biopark, located in Jerusalem, helps doctors conduct research
|
|
| Apr. 19, 2010 |
- |
"Swimming Against The Current"
9 Stocks on TASE Post Gains Even When the Market Doesn't
|
|
| Apr. 13, 2010 |
- |
Clal Biotechnology, Pontifax and Hadasit Bio-Holdings to invest $ 4 million in ProtAb, a wholly owned Hadasit Bio-Holdings portfolio company
The company is developing a novel monoclonal antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn’s Disease
|
|
| Mar. 28, 2010 |
- |
Hadassah Breakthrough Increases the Potential to Produce the Large Quantities of Human Embryonic Stem Cells Required For Transplantation
|
|
| Mar. 19, 2010 |
- |
Hadasit - One of "10 Promising Stocks for 2010"
|
|
| Mar. 11, 2010 |
- |
Hadasit Bio Holdings Exploits Its Competitive Advantage
As published in "Globes", March 10th, 2010
|
|
| Mar. 3, 2010 |
- |
Small But Promising Companies
New BioMed Index Attracts Investors in Israel Life Sciences
|
|
| Jan. 24, 2010 |
- |
Tel Aviv Stock Exchange to Launch BioMed Index
38 BioMed Companies on TASE. Index to Allow New Investment Vehicles
|
|
| Dec. 24, 2009 |
- |
KAHR Medical Raises 1.5 M Sheqels from Hadasit Bio-Holdings, Moves Towards Clinical Trial of Immune-system Diseases and Cancer
Invited to Present Preclinical Results at Major Scientific Conferences in Europe and the United States
|
|
| Dec. 6, 2009 |
- |
ProtAb, a Wholly Owned Subsidiary of Hadasit Bio-Holdings, Attracts Funding and Initiates the Manufacturing Process of its Lead Antibody in Preparation for Clinical Trials
|
|
| Nov. 17, 2009 |
- |
Hadasit Bio-Holdings Expands Activity to Diagnostic Markers for Cancer and Sets Up BioMarCare Technologies
The new company has begun a clinical trial of the first marker, for detection of various stages of breast cancer. HBL will inject 1.1 million NIS to bring the trial to completion.
|
|
| Sep. 15, 2009 |
- |
"An Innovation Factory in the Medical Field"
HBL bridges the gap between hospital research and industry
|
|
| Sep. 1, 2009 |
- |
Innovation Powerhouse Applies a New Model For Commercialization
How hadassah is leading Israel’s medical research
|
|
| Jul. 6, 2009 |
- |
Jerusalem Mayor Nir Barkat Visits BioTechnology Park at Hadassah Ein Kerem
Mayor calls the Jerusalem BioPark a central element in the making of Jerusalem
|
|
| Feb. 26, 2009 |
- |
KAHR's Third Generation Biologics Attract Financing
Published in BioWorld Today, Feb. 19th, 2009
|
